Publication Name	World Journal of Gastroenterology
Manuscript ID	66467
Country	Greece

Received	2021-03-28 15:15
Peer-Review Started	2021-03-28 15:22
To Make the First Decision
Return for Revision	2021-06-14 01:16
Revised	2021-06-28 15:16
Second Decision	2021-09-22 03:18
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-09-23 07:22
Articles in Press	2021-09-23 07:22
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-10-18 03:51
Publish the Manuscript Online	2021-10-20 07:18

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Frontier
Article Title	Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
Manuscript Source	Invited Manuscript
All Author List	Georgios Neokosmidis, Evangelos Cholongitas and Konstantinos Tziomalos
ORCID	Author(s) ORCID Number Georgios Neokosmidis http://orcid.org/0000-0003-1858-9098 Evangelos Cholongitas http://orcid.org/0000-0002-3645-582X Konstantinos Tziomalos http://orcid.org/0000-0002-3172-1594
Funding Agency and Grant Number
Corresponding Author	Konstantinos Tziomalos, MD, MSc, PhD, Associate Professor, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi street, Thessaloniki 54636, Greece. ktziomalos@yahoo.com
Key Words	Acetyl-CoA carboxylase inhibitors; Non-alcoholic steatohepatitis; Fibrosis; Steatosis; Firsocostat
Core Tip	Acetyl-CoA carboxylase inhibitors suppress de novo lipogenesis resulting in improvement in hepatic steatosis in both animal models and in patients with nonalcoholic fatty liver disease. However, the effects of these agents on hepatic fibrosis are inconsistent and they increase plasma triglyceride levels, casting doubt on their risk/benefit profile.
Publish Date	2021-10-20 07:18
Citation	Neokosmidis G, Cholongitas E, Tziomalos K. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit? World J Gastroenterol 2021; 27(39): 6522-6526
URL	https://www.wjgnet.com/1007-9327/full/v27/i39/6522.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i39.6522

Full Article (PDF)	WJG-27-6522.pdf
Full Article (Word)	WJG-27-6522.docx
Manuscript File	66467_Auto_Edited.docx
Answering Reviewers	66467-Answering reviewers.pdf
Audio Core Tip	66467-Audio core tip.aac
Conflict-of-Interest Disclosure Form	66467-Conflict-of-interest statement.pdf
Copyright License Agreement	66467-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	66467-Language certificate.pdf
Peer-review Report	66467-Peer-review(s).pdf
Scientific Misconduct Check	66467-Bing-Yan JP-1.jpg
Scientific Misconduct Check	66467-Bing-Wang LL-2.png
Scientific Editor Work List	66467-Scientific editor work list.pdf
CrossCheck Report	66467-CrossCheck report.pdf